Astellas Pharma (OTCMKTS:ALPMY) Sees Strong Trading Volume – Still a Buy?

Shares of Astellas Pharma Inc. (OTCMKTS:ALPMY) saw strong trading volume on Tuesday . 317,850 shares traded hands during mid-day trading, an increase of 212% from the previous session’s volume of 101,867 shares.The stock last traded at $14.42 and had previously closed at $14.38.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Citigroup cut shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 19th. Zacks Research cut Astellas Pharma from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 22nd. Three analysts have rated the stock with a Hold rating, According to MarketBeat, the stock presently has a consensus rating of “Hold”.

Astellas Pharma Stock Down 0.1%

The stock has a market cap of $26.00 billion, a PE ratio of 30.57 and a beta of 0.17. The business has a fifty day moving average of $13.38 and a 200-day moving average of $11.77. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.03 and a quick ratio of 0.80.

Astellas Pharma (OTCMKTS:ALPMY) last announced its quarterly earnings results on Thursday, October 30th. The company reported $0.30 EPS for the quarter, beating the consensus estimate of $0.20 by $0.10. Astellas Pharma had a return on equity of 22.21% and a net margin of 6.39%.The firm had revenue of $3.45 billion for the quarter, compared to analyst estimates of $3.14 billion. Equities research analysts anticipate that Astellas Pharma Inc. will post 0.42 earnings per share for the current year.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).